Circulating transforming growth factor-Β1 levels and the risk for kidney disease in African Americans

Kidney International

Volumn 76, Issue 1, 2009, Pages 72-80

  Suthanthiran, Manikkam ^a   Gerber, Linda M ^a   Schwartz, Joseph E ^a,b   Sharma, Vijay K ^a   Medeiros, Mara ^a   Marion, Rosemerie ^a   Pickering, Thomas G ^c   August, Phyllis ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

African Americans; Blood pressure; Hypertension kidney disease; PRA; TGF b1

Indexed keywords

ALBUMIN; MICROALBUMIN; RENIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; BODY MASS; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; KIDNEY DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; REGRESSION ANALYSIS; RISK ASSESSMENT; SEX DIFFERENCE; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; VALIDATION PROCESS;

ADULT; AFRICAN AMERICANS; BLOOD PRESSURE; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENIN; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 67449155931     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.66     Document Type: Article

References (46)

1. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358.
2. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
3. Huang Y, Border WA, Noble NA. Perspectives on blockade of TGFbeta overexpression. Kidney Int 2006; 69: 1713-1714.
4. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of anglotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462. Erratum in: N Engl J Med 1993 Jan 13;330(2):152.
5. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
6. Dillon JJ. Angiotensin-Converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropatAngiotensln-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol 2004; 24: 218-224.
7. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II In renal fibrosis. Hypertension 1998; 31 (Part 2): 181-188.
8. Antonlpillai I, Le TH, Soceneantu L et al. Transforming growth factor-beta is a renin secretagogue at plcomolar concentrations. Am J Physiol 1993; 265(Part 2): F537-F541.
9. Brezniceanu ML, Wei CC, Zhang SL et al. Transforming growth factor-beta 1 stimulates angiotensinogen gene expression in kidney proximal tubular cells. Kidney Int 2006; 69: 1977-1985.
10. Huang Y, Wongamorntham S, Kasting J et al. Renin Increases mesangial cell transforming growth factor-betal and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-113.
11. Wolf G, Mueller E, Stahl RA et al. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993; 92: 1366-1372.
12. Sharma K, Eltayeb BO, McGowan TA et al. Captoprll-induced reduction of serum levels of transforming growth factor-betal correlates with longterm renoprotectlon in insulin-dependent diabetic patients. Am J Kidney Dis 1999;34:818-823.
13. Whelton PK, Perneger TV, He J et al. The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. J Hum Hypertens 1996; 10: 683-689.
14. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
15. Xue JL, Eggers PW, Agodoa LY et al. Longitudinal study of racial and ethnic differences in developing end-stage renal disease among aged medicare beneficiaries. J Am Soc Nephrol 2007; 18: 1299-1306.
16. Hsu CY, Lin F, Vittinghoff E et al. Racial differences In the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003; 14: 2902-2907.
17. Newsome BB, McClellan WM, Allison JJ et al. Racial differences In the competing risks of mortality and ESRD after acute myocardial infarction. Am J Kidney Dis 2008; 52: 251-261. e-pub 12 May 2008.
18. Suthanthiran M, Khanna A, Cukran D et al. Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int 1998; 53: 639-644.
19. Suthanthiran M, Li B, Song JO et al. Transforming growth factor-beta 1 hyperexpression In African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 2000; 97: 3479-3484.
20. Grundy SM, Brewer Jr HB, Cleeman JI et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
21. Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens 2001; 15: 17-25.
22. Keeton MR, Curriden SA, van Zonneveld AJ et al. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem 1991; 266: 23048-23052.
23. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174.
24. Ferdinand KC. Hypertension In minority populations. J Clin Hypertens (Greenwich) 2006; 8: 365-368.
25. Waldegger S, Klingel K, Barth P et al. h-sgk serine-threonine protein kinase gene as transcriptional target of transforming growth factor beta in human intestine. Gastroenterology 1999; 116: 1081-1088.
26. Waldegger S, Barth P, Raber G et al. Cloning and characterization of a putative human serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume. Proc Natl Acad Sci USA 1997; 94: 4440-4445.
27. Lang F, Klingel K, Wagner CA et al. Deranged transcriptional regulation of cell-volume-sensltive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci USA 2000; 97: 8157-8162.
28. Chen SY, Bhargava A, Mastroberardino L et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA 1999; 96: 2514-2519.
29. Náray-Fejes-Tóth A, Canessa C, Cleaveland ES et al. sgk is an aldosterone-induced kinase in the renal collecting duct. Effects on epithelial na+ channels. J Biol Chem 1999; 274: 16973-16978.
30. August P, Suthanthiran M. Transforming growth factor beta signaling, vascular remodeling, and hypertension. N Engl J Med 2006; 354: 2721-2723.
31. Dahly AJ, Hoagland KM, Flasch AK et al. Antihypertensive effects of chronic antl-TGF-beta antibody therapy in Dahl S rats. Am J Physiol Regul lntegr Comp Physiol 2002; 283: R757-R767.
32. Zacchigna L, Vecchione C, Notte A et al. Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell 2006; 124: 929-942.
33. Colin Bell A, Adair LS, Popkin BM. Ethnic differences in the association between body mass index and hypertension. Am J Epidemiol 2002; 155: 346-353.
34. Iseki K, Ikemiya Y, Kinjo K et al. Body mass Index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65: 1870-1876.
35. Hsu CY, McCulloch CE, Iribarren C et al. Body mass Index and risk for endstage renal disease. Ann Intern Med 2006; 144: 21-28.
36. Fain JN, Tichansky DS, Madan AK. Transforming growth factor beta1 release by human adipose tissue is enhanced in obesity. Metabolism 2005; 54: 1546-1551.
37. Porreca E, Di Febbo C, Vitacolonna E et al. Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin. Am J Hypertens 2002; 15: 759-765.
38. Scaglione R, Argano C, di Chiara T et al. Central obesity and hypertensive renal disease: association between higher levels of BMI, circulating transforming growth factor beta1 and urinary albumin excretion. Blood Press 2003; 12: 269-276.
39. Scaglione R, Argano C, Corrao S et al. Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial. J Hypertens 2005; 23: 657-664.
40. Tang H, Quertermous T, Rodriguez B et al. Genetic structure, selfidentified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 2005; 76: 268-275.
41. Saharinen J, Hyytiainen M, Taipale J et al. Latent transforming growth factor-beta binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 1999; 10: 99-117.
42. Huang XR, Chung AC, Wang XJ et al. Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am J Physiol Renal Physiol 2008; 295: F118-F127. e-pub 30 Apr 2008.
43. Huang XR, Chung AC, Zhou L et al. Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol 2008; 19: 233-242. e-pub 23 Jan 2008.
44. Gerber LM, Sievert LL, Warren K et al. Hot flashes are associated with increased ambulatory systolic blood pressure. Menopause 2007; 14: 308-315.
45. Pickering TG, Hall JE, Appel LJ et al. Recommendations for blood pressure measurement In humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45: 142-161.
46. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37: 1811-1819.